Thomas Peterson III Sells 70,000 Shares of Evolent Health Inc (EVH) Stock

Evolent Health Inc (NYSE:EVH) COO Thomas Peterson III sold 70,000 shares of Evolent Health stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $27.50, for a total value of $1,925,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Thomas Peterson III also recently made the following trade(s):

  • On Thursday, August 30th, Thomas Peterson III sold 30,000 shares of Evolent Health stock. The stock was sold at an average price of $25.00, for a total value of $750,000.00.
  • On Monday, July 2nd, Thomas Peterson III sold 10,000 shares of Evolent Health stock. The stock was sold at an average price of $21.21, for a total value of $212,100.00.

EVH stock opened at $27.65 on Friday. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -39.50 and a beta of 1.22. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.59 and a quick ratio of 2.59. Evolent Health Inc has a one year low of $10.30 and a one year high of $28.20.

Evolent Health (NYSE:EVH) last released its earnings results on Tuesday, August 7th. The technology company reported ($0.03) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. The firm had revenue of $144.51 million during the quarter, compared to analysts’ expectations of $141.90 million. Evolent Health had a negative net margin of 9.84% and a negative return on equity of 1.82%. sell-side analysts expect that Evolent Health Inc will post -0.35 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Metropolitan Life Insurance Co. NY grew its stake in shares of Evolent Health by 12.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 22,031 shares of the technology company’s stock valued at $464,000 after buying an additional 2,459 shares during the period. State Board of Administration of Florida Retirement System grew its stake in shares of Evolent Health by 16.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 21,773 shares of the technology company’s stock valued at $458,000 after buying an additional 3,150 shares during the period. Legal & General Group Plc grew its stake in shares of Evolent Health by 16.8% during the 1st quarter. Legal & General Group Plc now owns 26,437 shares of the technology company’s stock valued at $377,000 after buying an additional 3,811 shares during the period. Rhumbline Advisers grew its stake in shares of Evolent Health by 8.2% during the 1st quarter. Rhumbline Advisers now owns 57,923 shares of the technology company’s stock valued at $825,000 after buying an additional 4,370 shares during the period. Finally, Swiss National Bank grew its stake in shares of Evolent Health by 4.8% during the 1st quarter. Swiss National Bank now owns 104,000 shares of the technology company’s stock valued at $1,482,000 after buying an additional 4,800 shares during the period.

Several research analysts recently issued reports on EVH shares. KeyCorp lifted their price objective on Evolent Health from $19.00 to $24.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 30th. Piper Jaffray Companies began coverage on shares of Evolent Health in a research note on Monday, June 4th. They issued an “overweight” rating and a $30.00 target price for the company. TheStreet raised shares of Evolent Health from a “d+” rating to a “c-” rating in a research note on Monday, June 4th. SunTrust Banks lifted their target price on shares of Evolent Health and gave the stock a “buy” rating in a research note on Thursday, June 7th. Finally, MED lifted their target price on shares of Evolent Health from $22.00 to $31.00 and gave the stock an “outperform” rating in a research note on Monday, June 18th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $28.67.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Further Reading: What is a closed-end mutual fund (CEF)?

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply